Skip to main content
Advertising

Originally published Wednesday, April 18, 2012 at 7:15 AM

  • Share:
             
  • Comments (0)
  • Print

Roche to end bid to buy diagnostics firm Illumina

Swiss drugmaker Roche Holding AG will end its offer to acquire U.S. diagnostics firm Illumina Inc. for about $6.5 billion after forecasting that Illumina shareholders will reject its dissident slate of directors.

The Associated Press

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

NEW YORK —

Swiss drugmaker Roche Holding AG will end its offer to acquire U.S. diagnostics firm Illumina Inc. for about $6.5 billion after forecasting that Illumina shareholders will reject its dissident slate of directors.

Roche had announced in January an offer to buy the San Diego company's shares for $44.50 each. It then raised that to $51 last month, after Illumina's board rejected the bid. But Roche said Wednesday it decided not to extend the latest offer past an April 20 expiration.

Two shareholder advisory firms have recommended that Illumina shareholders reject Roche's offer, and Illumina had said the new offer remained insufficient.

Shortly after Roche's Wednesday morning announcement, Illumina said shareholders at its annual meeting elected Illumina nominees to its board and rejected several Roche proposals, including one to increase the board's size.

"We are pleased that Roche has decided not to extend its inadequate offer to acquire Illumina and that we can now return our full focus to growing our business, making the most of the expanding opportunities in our space, and delivering superior results for our customers and stockholders," Illumina CEO Jay T. Flatley said in a statement from the company.

Illumina makes instruments for genetic analysis. Roche's product portfolio includes the blockbuster cancer drug Avastin. It is the world's sixth largest drugmaker based on revenue, according to the data firm IMS Health.

Roche said its increased offer represented an 88 percent premium over Illumina's closing stock price on Dec. 21, which was the day before market rumors about a potential deal between the companies drove those shares significantly higher.

CEO Severin Schwan had said last week it still believed that the $51 per-share price was fair based on available public information. But he added that "if Illumina were to engage with us, we would consider any information supporting Illumina's contention that our offer undervalues the company and its prospects."

The Swiss company said Wednesday it will keep looking for ways expand its diagnostics business.

Shares of Illumina initially fell as much as 8 percent but ended trading up 51 cents at $44.51 while broader trading indexes declined. U.S.-traded shares of Roche climbed 41 cents to $44.47.

News where, when and how you want it

Email Icon


Advertising